Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL)
Article in Cancer Medicine (July 2024)
The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.
Article in Cancer Medicine (July 2024)
Article in Experimental and Therapeutic Medicine (May 2024)
Article in Therapie (April 2024)